Viewing nowCombinationDucadipin 60/2.5 mg Tablet
Fimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.

MFDS item code 202300119 · Approved 2023.01.06 · Insurance code 640904440
Treatment of essential hypertension not controlled with fimasartan monotherapy
This medicine is used in patients with essential hypertension whose blood pressure is not adequately controlled with Pimasartan Potassium monotherapy.
The recommended dose is 1 tablet once daily, taken with water, with or without food. It is recommended to take this medicine at the same time each day, if possible (e.g., in the morning). Before starting this medicine, it is recommended to adjust the dose of fimasartan. However, if blood pressure is not controlled as described below, switching directly to this medicine may be considered. ㆍ 30/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 30 mg monotherapy. ㆍ 60/2.5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy. ㆍ 60/5 mg: For patients whose blood pressure is not adequately controlled with fimasartan 60 mg monotherapy or this medicine 60/2.5 mg. Patients taking fimasartan and S-amlodipine (amlodipine) concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience. Elderly patients No initial dose adjustment is necessary for elderly patients aged 70 years or younger. Patients with renal impairment No dose adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance 30 ~ 80 mL/min). For patients with severe renal impairment (creatinine clearance < 30 mL/min), start treatment with the 30 mg fimasartan dose of this medicine. Patients with hepatic impairment No dose adjustment is necessary in patients with mild hepatic impairment. However, this medicine should not be administered to patients with moderate to severe hepatic impairment.
The safety and efficacy of this medicine in pediatric and adolescent patients aged 18 years or younger have not been established.
This medication can cause serious harm or death to the fetus and newborn if taken during the second or third trimester of pregnancy; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients who have allergies to this medication's active ingredients or similar compounds, those who are pregnant or breastfeeding, patients undergoing renal dialysis, patients with moderate to severe liver impairment, patients with bile duct obstruction, certain kidney disease patients, patients with lactose intolerance, patients with severe aortic stenosis, patients in shock, etc., should not take this medication. Patients with reduced blood volume or reduced renal function, patients with renal artery hypertension, patients with aortic and mitral valve stenosis, patients with severe hypotension, elderly patients, and those with allergies to certain pigments should take this medication with caution, ensuring close monitoring of their condition. This medication can cause a variety of side effects, including headache, dizziness, facial swelling, urination disturbances, insomnia, and flushing; if these symptoms persist or worsen, consultation with healthcare professionals is advised. During the initial intake or when increasing the dosage, blood pressure may drop too low, so attention should be paid to symptoms of hypotension, and if blood pressure becomes too low, the patient should be laid down and, if necessary, receive fluid therapy. Especially in patients with heart failure or weakened kidney function, there is a risk of elevated potassium levels in the blood, necessitating regular blood tests. This medication can interact with other antihypertensives, diuretics, potassium supplements, certain antibiotics, and analgesics; therefore, patients should inform healthcare professionals of any concurrent medications. Women who are pregnant or breastfeeding are advised against taking this medication, and if necessary, should consult their physician to use safe alternative medications. Children under 18 years of age should not use this medication, as its safety and efficacy in this population have not been established. In cases of overdose, severe hypotension, cardiac arrhythmias, shock, etc., may occur, so immediate emergency treatment is required; caution should also be exercised as blood pressure may recover slowly after discontinuation. This medication should be kept out of reach of children and stored in its original packaging to maintain its quality.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to light, so it should be stored in a light-resistant container. Additionally, it is important to store it in a cool room temperature, between 1°C and 30°C, to maintain its effectiveness.
Yellow, rounded rectangular film-coated tablet
30 tablets/bottle, 300 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 7.48mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 66.01mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
NBK Pharmaceutical Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Ajou Pharmaceuticals Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Kips Biopharma Co., Ltd.
CombinationFimasartan Potassium Trihydrate 33.005mg · S-Amlodipine Besylate 2.5 Hydrate 3.74mg
Tablet · Prescription medication · Combination
Bionex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.